The HOYA MiYOSMART was the first of the new generation of myopia control spectacle lenses, with evidence for slowing myopia progression by at least half. Learn more about efficacy, the lens design, visual outcomes and more.
The SightGlass DOT 0.2 lens presents a new theory in myopia control, with clinical trial evidence of efficacy in children from 6 to 10 years of age. Diffusion Optics Technology (DOT) incorporates microdots to modulate retinal contrast; it does not employ defocus as for other optical treatments. Learn more here.
The contrast theory in myopia development and control is based on links between retinal cone expressions, genetics and myopia. This is distinct from peripheral defocus and simultaneous defocus theories and underpins the new SightGlass DOT 0.2 spectacle lens for myopia control. Learn more here.
A dose-response is where an increasing amount of a medication or intervention is correlated with a better clinical outcome. When it comes to myopia control, we investigate the evidence for a dose-response with spectacle, contact lens, atropine and outdoor time interventions.
Our Q&A format explores new technologies, products and research with experts. In this interview, Dr Sherman Tung, optometrist from Canada, shares his experience with The SightGlass Vision DOT 0.2 Lens in his practice, from prescribing to parent explanations and clinical outcomes.
Spectacle lenses which effectively control myopia progression are the next phase in widespread uptake of myopia management. Learn more about the Essilor Stellest lens, from myopia control to vision and visual function outcomes.
The newest myopia controlling spectacles can both correct and control myopia as effectively as contact lens options. How do Defocus Incorporated Multiple Segments (DIMS) and HIghly Aspherical Lenslet Target (H.A.L.T.) technology spectacle lenses work? Here we investigate and compare their design, presumed mechanism and comparative efficacy for myopia control, based on published research.
Providing spectacle correction is one of the cornerstones of primary eye care, and myopia controlling spectacles can both correct and control myopia. Here we explore the current myopia controlling spectacle lenses which have or are being commercialized, for which peer-reviewed publications are available – their design, presumed mechanism and comparative efficacy.
Here we explore an overview of spectacle prescribing for myopia management – from when to use single vision, to progressive and bifocal designs, new myopia control specific designs, and whether to fully or under-correct.
There’s a little more to think about in the important role spectacle lenses play in myopia management. Even if we prescribe contact lenses, our young myopes are most likely to need a back up spectacle lens option. Children prescribed atropine will need the best spectacle lens prescribed for them to minimise the impact of any side effects.
